Skip to content

Menu

Sheppard, Mullin, Richter & Hampton LLP logo
HomePracticeContact

FDA Law Update

Current Issues Affecting FDA-Regulated Companies

Biotechnology

Subscribe to Biotechnology
FDA-Blog-Image-Law-660x283

Biogen Settlement Summary

By Eve Costopoulos & Dominick DiSabatino on October 6, 2022
Posted in Biotechnology

On Monday September 26, the Department of Justice announced a settlement resolving a lawsuit filed by former employee Michael Bawduniak (the “Plaintiff”) against Biogen Inc. (the “Company”) under the qui tam provisions of the federal False Claims Act.[1]…

Continue Reading Biogen Settlement Summary

Subscribe
Sheppard Mullin Blogs
Podcasts

Stay Connected

Facebook LinkedIn Twitter Subscribe to this blog via RSS

Topics

Topics

Archives

Recent Upates

  • FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer
  • FDA Draft Guidance Signifies Acceptance of the Term “Milk” to Describe Plant-Based Alternatives
  • OIG Advisory Opinion Alert: Medical Flights for Patient Access
  • FDA Issues Warning Letter to RightEye, LLC For Misbranding and Adulteration
  • 2023 Top-of-Mind Issues for Life Sciences Companies

FDA Law Update

Facebook LinkedIn Twitter Subscribe to this blog via RSS
Privacy PolicyDisclaimer
Copyright © 2023, Sheppard, Mullin, Richter & Hampton LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.

Agree